Literature DB >> 559938

Binding of soluble immune complexes in serum of patients with Hodgkin's disease to tissue cultures derived from the tumor.

J C Long, C L Hall, C A Brown, C Stamatos, S A Weitzman, K Carey.   

Abstract

We examined 90 serums from patients with Hodgkin's disease for immune complexes and for reactivity with established monolayer tissue cultures prepared from the tumor. All 23 serums with immune complex levels greater than 20 microgram per milliliter were found to react with cultured cells of patients with Hodgkin's disease when tested with antiserums against immunoglobulin heavy and light chains and the C3 component of complement. Five of 11 serums with borderline elevations of immune complexes (10 to 20 microgram per milliliter) and only four of 56 with levels less than 10 microgram per milliliter reacted. Absorption of patients' serums with cultured cells removed immune complexes and eliminated binding to monolayers. Immune-complex-containing serums from 19 control patients did react with cultured cells of patients with Hodgkin's disease; none of serums reacted with normal cultured spleen. Antibodies within complement-containing immune complexes in serums of patients with Hodgkin's disease react with an antigen on the surface of cultured cells of such patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 559938     DOI: 10.1056/NEJM197708112970602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Serum antibodies to a normal cellular protein (P-65) in patients with Hodgkin's disease.

Authors:  F W Hirsch; J Scholl; G Dölken
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 2.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

3.  Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.

Authors:  W E Brandeis; C Tan; Y Wang; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

4.  Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.

Authors:  W E Brandeis; L Helson; Y Wang; R A Good; N K Day
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

5.  Evidence for a disease specific antigen in circulating immune complexes in ankylosing spondylitis.

Authors:  C Bruneau; H Bonin
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

6.  Subpopulations of human T lymphocytes. XVI. Maldistribution of T cell subsets associated with abnormal locomotion of T cells in untreated adult patients with Hodgkin's disease.

Authors:  S Gupta
Journal:  Clin Exp Immunol       Date:  1980-10       Impact factor: 4.330

7.  Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.

Authors:  S Gupta; G Fernandes
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

8.  Consistent fluctuations in quantities of circulating immune complexes during progressive and regressive phases of tumor growth.

Authors:  J C Jennette
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 9.  Malignant lymphomas as tumours of the immune system.

Authors:  C W Berard; J Cossman; E S Jaffe
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.